VTRS Stock Analysis: Viatris | NASDAQ
Drug Manufacturers - Specialty & Generic | NASDAQ, USA | Market Cap: 20.238m USD | 12M Return: 82.8% | US92556V1061 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 156M
EPS Trend: -88.9%
Qual. Beats: 5
Rev. Trend: -78.6%
Qual. Beats: 5
Warnings
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Viatris Inc. is a U.S.-headquartered global healthcare company that develops, manufactures, and distributes a broad portfolio of prescription brands, generics, complex generics, and biosimilars across more than a dozen therapeutic areas, including cardiovascular, oncology, immunology, respiratory, and dermatology. The company reports through four geographic segments-Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets-and sells to wholesalers, distributors, retailers, payers, governments, and institutions through a mix of traditional and specialty pharmacy channels. Its marketed brands include well-known names such as Lipitor, Lyrica, Viagra, Celebrex, EpiPen, and Creon, and it maintains collaboration agreements with Mapi Pharma, Revance Therapeutics, and Theravance Biopharma to extend its pipeline.
Viatris was formed in November 2020 through the combination of Mylan and Pfizers established-products (Upjohn) business, which is reflected in its 2020 IPO date. As a participant in the generic and biosimilar pharmaceutical industry, the company operates in a sector characterized by patent-driven brand competition alongside high-volume, lower-margin off-patent drug sales, with growth increasingly tied to complex generics and biosimilars as blockbuster biologics lose exclusivity.
- Generic pricing pressure and competition erodes Developed Markets revenue
- Greater China segment exposed to geopolitical and VBP pricing risks
- High debt burden from Upjohn merger limits capital allocation flexibility
| Net Income: -410.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 0.93 > 1.0 |
| NWC/Revenue: 25.17% < 20% (prev 18.71%; Δ 6.46% < -1%) |
| CFO/TA 0.07 > 3% & CFO 2.33b > Net Income -410.7m |
| Net Debt (12.4b) to EBITDA (2.64b): 4.69 < 3 |
| Current Ratio: 1.58 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.16b) vs 12m ago -0.83% < -2% |
| Gross Margin: 34.83% > 18% (prev 36.61%; Δ -1.78% > 0.5%) |
| Asset Turnover: 40.13% > 50% (prev 36.75%; Δ 3.38% > 0%) |
| Interest Coverage Ratio: -0.18 > 6 (EBIT TTM -87.2m / Interest Expense TTM 480.0m) |
| A: 0.11 (Total Current Assets 10.1b - Total Current Liabilities 6.35b) / Total Assets 35.0b |
| B: -0.01 (Retained Earnings -330.7m / Total Assets 35.0b) |
| C: -0.00 (EBIT TTM -87.2m / Avg Total Assets 36.7b) |
| D: 0.69 (Book Value of Equity 14.3b / Total Liabilities 20.8b) |
| Altman-Z'' = 1.37 = BB |
| DSRI: 0.98 (Receivables 3.67b/3.60b, Revenue 14.7b/14.1b) |
| GMI: 1.05 (GM 36.61% / 34.83%) |
| AQI: 0.95 (AQ_t 0.64 / AQ_t-1 0.67) |
| SGI: 1.04 (Revenue 14.7b / 14.1b) |
| TATA: -0.08 (NI -410.7m - CFO 2.33b) / TA 35.0b) |
| Beneish M = -3.00 (Cap -4..+1) = AA |
As of October 12, 2026, the stock is trading at USD 17.64 with a total of 8,831,095 shares traded. Over the past week, the price has changed by +0.23%, over one month by +6.91%, over three months by +8.77% and over the past year by +82.84%.
Current recommended Stop Loss: 17.00 (which is 3.6% or 1.4 ATR below the current price).
Viatris has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy VTRS.
- StrongBuy: 6
- Buy: 1
- Hold: 4
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 19.7 | 11.7% |
P/E Forward = 6.3816
P/S = 1.3733
P/B = 1.3805
P/EG = 1.0487
Revenue TTM = 14.7b USD
EBIT TTM = -87.2m USD
EBITDA TTM = 2.64b USD
Long Term Debt = 11.6b USD (from longTermDebt, last quarter)
Short Term Debt = 1.85b USD (from shortTermDebt, last quarter)
Debt = 13.9b USD (from shortLongTermDebtTotal, last quarter) + Leases 275.1m
Net Debt = 12.4b USD (calculated: Debt 13.9b - CCE 1.51b)
Enterprise Value = 32.6b USD (20.2b + Debt 13.9b - CCE 1.51b)
Interest Coverage Ratio = -0.18 (Ebit TTM -87.2m / Interest Expense TTM 480.0m)
EV/FCF = 17.42x (Enterprise Value 32.6b / FCF TTM 1.87b)
FCF Yield = 5.74% (FCF TTM 1.87b / Enterprise Value 32.6b)
FCF Margin = 12.71% (FCF TTM 1.87b / Revenue TTM 14.7b)
Net Margin = -2.79% (Net Income TTM -410.7m / Revenue TTM 14.7b)
Gross Margin = 34.83% ((Revenue TTM 14.7b - Cost of Revenue TTM 9.60b) / Revenue TTM)
Gross Margin QoQ = 38.77% (prev 32.90%)
Tobins Q-Ratio = 0.93 (Enterprise Value 32.6b / Total Assets 35.0b)
Interest Expense / Debt = 3.45% (Interest Expense 480.0m / Debt 13.9b)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -68.9m (EBIT -87.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.58 (Total Current Assets 10.1b / Total Current Liabilities 6.35b)
Debt / Equity = 0.97 (Debt 13.9b / totalStockholderEquity, last quarter 14.3b)
Debt / EBITDA = 4.69 (Net Debt 12.4b / EBITDA 2.64b)
Debt / FCF = 6.62 (Net Debt 12.4b / FCF TTM 1.87b)
Total Stockholder Equity = 14.7b (last 4 quarters mean from totalStockholderEquity)
RoA = -1.12% (Net Income -410.7m / Total Assets 35.0b)
RoE = -2.79% (Net Income TTM -410.7m / Total Stockholder Equity 14.7b)
RoCE = -0.33% (EBIT -87.2m / Capital Employed (Equity 14.7b + L.T.Debt 11.6b))
RoIC = -0.23% (negative operating profit) (NOPAT -68.9m / Invested Capital 29.8b)
WACC = 6.01% (E(20.2b)/V(34.1b) * Re(8.27%) + D(13.9b)/V(34.1b) * Rd(3.45%) * (1-Tc(0.21)))
Discount Rate = 8.27% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -86.75 | Cagr: -1.72%
[DCF] Terminal Value 76.72% ; FCFF base≈1.80b ; Y1≈1.97b ; Y5≈2.46b
[DCF] Fair Price = 21.97 (EV 37.6b - Net Debt 12.4b = Equity 25.2b / Shares 1.15b; r=8.35% [WACC [floored]]; 5y FCF grow 10.50% → 2.50% )
EPS Correlation: -88.88 | EPS CAGR: -8.09% | SUE: 1.77 | # QB: 5
Revenue Correlation: -78.58 | Revenue CAGR: -2.96% | SUE: 0.95 | # QB: 5
EPS current Quarter (2026-09-30): EPS=0.65 | Chg30d=-0.77% | Revisions=-40% | Analysts=10
EPS current Year (2026-12-31): EPS=2.52 | Chg30d=+0.65% | Revisions=+50% | GrowthEPS=+7.1% | GrowthRev=+3.4%
EPS next Year (2027-12-31): EPS=2.67 | Chg30d=+0.18% | Revisions=+0% | GrowthEPS=+6.2% | GrowthRev=+1.7%
[Analyst] Revisions Ratio: +7% (up=6, down=5)